Cetris Oncology Solutions, a San Diego, CA-based precision oncology and translational science company, raised $10M in Series C funding.
The round, which brought the total amount to $42M, saw participation from undisclosed investors.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO and President Peter Elman, Certis Oncology Solutions is a life science technology company focused on combining AI-directed drug development with advanced functional testing. Its product is Oncology Intelligence™ — highly predictive therapeutic response data derived from advanced models of cancer.
Since its founding in 2016, the company has offered personalized functional testing to help inform individual cancer treatment decisions, an approach gaining wide support from cancer researchers and oncology clinicians worldwide. Using its patent-pending artificial intelligence/machine learning platform, and more clinically relevant, patient-derived tumor models, the company brings certainty to drug development decisions and helps secure clear and compelling evidence of drug efficacy. Certis operates a CLIA-certified laboratory in Sorrento Valley, the heart of San Diego’s life sciences industry.
The company also named John R. Tozzi Chairman of its Board of Directors.
FinSMEs
17/01/2024